Sherbenou and Mukherjee labs receive an award from the Cancer League of Colorado for a collaborative proposal. The labs will combine their complementary expertise to investigate the molecular by which mRNA translation inhibitors are efficacious for the treatment of relapsed/refractory multiple myeloma.
